RT Journal Article
SR Electronic
T1 Molecular characterization of non-small cell lung cancer tumors in Latin American patients from Brazil, Chile and Peru uncovers novel potentially driver mutations
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.09.11.20171025
DO 10.1101/2020.09.11.20171025
A1 Sepúlveda-Hermosilla, Gonzalo
A1 Blanco, Alejandro
A1 Freire, Matías
A1 Lizana, Rodrigo
A1 Cáceres-Molima, Javier
A1 Ampuero, Diego
A1 Pérez, Paola
A1 Ramos, Liliana
A1 Aren, Osvaldo
A1 Chernilo, Sara
A1 Spencer, María Loreto
A1 Flores, Jacqueline
A1 Bernal, Giuliano
A1 Olea, Mónica Ahumada
A1 Rasse, Germán
A1 Sánchez, Carolina
A1 Marcelain, Katherine
A1 Rivas, Solange
A1 Amorim, Maria Galli de
A1 Branco, Gabriela
A1 Nunes, Diana Noronha
A1 Dias-Neto, Emmanuel
A1 Freitas, Helano C.
A1 Fernández, Cristina
A1 ,
A1 Assar, Rodrigo
A1 Armisén, Ricardo
YR 2020
UL http://medrxiv.org/content/early/2020/09/13/2020.09.11.20171025.abstract
AB Introduction Therapies that target activating Egfr, Alk, Ros1 and other mutations have become first-line treatments that improve NSCLC patient’s life expectancy. Latin-American patients are poorly represented in clinical trials and in genomic databases, thus little is known about the prevalence of actionable mutations in this population. This study characterizes, for the first time, the somatic mutations found in 52 actionable genes, and describe a novel set of potentially actionable mutations, in NSCLC patients from Chile, Brazil and Peru, while correlating these genomic occurrences with relevant clinical, demographic and pathology aspects.Methods 1732 subjects diagnosed with NSCLC were analyzed. DNA and RNA were sequenced using a 52 genes NGS panel. Mutations were annotated using the Variant Effect Predictor, COSMIC, OncoKB and the Cancer Genome Interpreter to categorize somatic mutations.Results We found a total of 1713 mutations with 626 (36.5%) novel, potentially driver mutations. 66.1% of these novel mutations were predicted as Tier 1 driver mutations. Actionable mutations for Ret and Alk were more prevalent in Brazil than in Chile, whereas Met exon-14 skipping was significantly enriched in Chile. In Peru, Egfr is higher while Kras is lower. A high number of novels potentially driver mutations in know NSCLC actionable genes, such as Alk, Erbb2, Ret, Met, and Ros1, was found.Conclusions The analysis of many Latin America subjects revealed a significant number of clinically actionable but also novel somatic mutations in cancer genes highlighting the importance of including less-represented populations in clinical trials and molecular studies.Competing Interest StatementGS, AB, RA, RAC, MF, LR, DA, RL, JC and PP were Pfizer Chile employees. HF, EDN, DNN, GPB, MGA, CF, GB, JF, MA, SC, OA, MLS, GR, CS, KM and SR received a grant and non-financial support for to perform this work for CEMP Pfizer Chile. Outside this work, HF discloses personal fees and non-financial support from Pfizer and BMS and non-financial support from AstraZeneca and Roche.Clinical TrialNCT03220230Funding StatementThis work received support from the Chilean Government CORFO International Center of Excellence Program (Grant # 13CEE2-21602) and Thermo Fisher Scientific. The funding sources were not involved in the study design, the collection, analysis and interpretation of data; in the writing of the report, neither in the decision to submit the article for publication.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:CONEP SEPN 510 Norte- Bloco A- 3DEGREE Andar- Edificio Ex-INAN, Unidade II - Ministerio da Saude Brasilia, DF 70750-521 BRAZIL Comite Etico Cientifico Av. Salvador 364, Servicio de Salud Metropolitano Oriente Providencia, SANTIAGO, RM 7500922 CHILE Comite de Etica Hospital Clinico Universidad de Chile Avenida Santos Dumont 999 Santiago, RM 8380456 CHILE Comite Etico Cientifico. Servicio de Salud Concepcion San Martin 1436 Concepcion, REGION DEL BIO BIO 4070038 CHILE Comite Institucional de Bioetica de VIA LIBRE(CIB) Jr. Paraguay 490, Cercado de Lima Lima, LIMA, PERU 01 PERU Comite de Etica en Investigacion del INEN Av. Angamos Este 2520, Surquillo 15038 Lima PERU Comite Institucional de Bioetica Via Libre Jr Paraguay 490 Lima PERU Comite Institucional de Etica en Investigacion Hospital Nacional Hipolito UNANUE Av. Cesar Vallejo 1390, El Agustino Lima PERUAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data generated or analysed during this study are included in this published article (and its supplementary information files).